Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874117 · ClinicalTrials.gov registry record · NA
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
A NA study of Kidney Failure, Chronic and Hemodialysis, sponsored by Palo Alto Veterans Institute for Research.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 3
- Study locations
NCT03874117: Completed NA study of Kidney Failure, Chronic and Hemodialysis, sponsored by Palo Alto Veterans Institute for Research.
NCT03874117 is a NA study of Kidney Failure, Chronic and Hemodialysis that has completed, run by Palo Alto Veterans Institute for Research. The registered enrollment target is 58 participants, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03874117, a NA study of Kidney Failure, Chronic and Hemodialysis, has completed, sponsored by Palo Alto Veterans Institute for Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
Primary Outcome
Kidney Disease Quality of Life: Health-related quality of life, with higher scores being better. Minimum is 0, maximum is 100.
Conditions Studied
Interventions
- OTHER Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis
- OTHER Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Study Locations (3)
California
- VA Palo Alto Health Care System - Palo Alto
- Santa Clara Valley Medical Center - San Jose
- Satellite HealthCare - San Jose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2025-05-31 |
| Phase | NA |
What the finished NCT03874117 record still lists
NCT03874117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 330-participant average among 23 other Kidney Failure, Chronic trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Kidney Failure, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis is the first listed.
NCT03874117 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03874117 about?
NCT03874117 is a clinical study titled "Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function". The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
What is the current status of trial NCT03874117?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2018-07-01. Estimated completion is 2025-05-31.
What conditions does trial NCT03874117 study?
This clinical trial studies the following conditions: Kidney Failure, Chronic, Hemodialysis.
What interventions are being tested in trial NCT03874117?
The interventions under investigation include: Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis (OTHER), Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis (OTHER).
Who is sponsoring clinical trial NCT03874117?
This trial is sponsored by Palo Alto Veterans Institute for Research, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03874117 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Failure, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03874117's enrollment target sits among peer trials
58 11th of 23 higher than 11 of 23 other Kidney Failure, Chronic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Failure, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Peritoneal Dialysis Patients (PDEX)
COMPLETED · NA
-
Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStage® System One™
COMPLETED · NA
-
Project to Improve Communication About Serious Illness--Hospital Study: Pragmatic Trial (Trial 1)
COMPLETED · NA
-
Multidisciplinary Inpatient Palliative Care Intervention
COMPLETED · NA
-
Dietary Maneuvers to Reduce Production of Colon-Derived Uremic Solutes
COMPLETED · NA
-
Resistance Training and Diet in Patients With Chronic Renal Failure
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI